Search

Your search keyword '"Shimoda, Haruko"' showing total 20 results
Start Over Author "Shimoda, Haruko" Search Limiters Available in Library Collection
20 results on '"Shimoda, Haruko"'

1. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator

Author

Kameda, Takuro, Shide, Kotaro, Yamaji, Takumi, Kamiunten, Ayako, Sekine, Masaaki, Taniguchi, Yasuhiro, Hidaka, Tomonori, Kubuki, Yoko, Shimoda, Haruko, Marutsuka, Kousuke, Sashida, Goro, Aoyama, Kazumasa, Yoshimitsu, Makoto, Harada, Taku, Abe, Hiroo, Miike, Tadashi, Iwakiri, Hisayoshi, Tahara, Yoshihiro, Sueta, Mitsue, Yamamoto, Shojiro, Hasuike, Satoru, Nagata, Kenji, Iwama, Atsushi, Kitanaka, Akira, and Shimoda, Kazuya

Published
2015
Full Text
View/download PDF

2. Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma

Author

Kameda, Takuro, primary, Shide, Kotaro, additional, Tahira, Yuki, additional, Sekine, Masaaki, additional, Sato, Seiichi, additional, Ishizaki, Junzo, additional, Takeuchi, Masanori, additional, Akizuki, Keiichi, additional, Kamiunten, Ayako, additional, Shimoda, Haruko, additional, Toyama, Takanori, additional, Maeda, Kouichi, additional, Yamashita, Kiyoshi, additional, Kawano, Noriaki, additional, Kawano, Hiroshi, additional, Hidaka, Tomonori, additional, Yamaguchi, Hideki, additional, Kubuki, Yoko, additional, Kitanaka, Akira, additional, Matsuoka, Hitoshi, additional, and Shimoda, Kazuya, additional

Published
2022
Full Text
View/download PDF

3. R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm

Author

Shide, Kotaro, Kameda, Takuro, Markovtsov, Vadim, Shimoda, Haruko K., Tonkin, Elizabeth, Fang, Shuling, Liu, Chian, Gelman, Marina, Lang, Wayne, Romero, Jason, McLaughlin, John, Bhamidipati, Somasekhar, Clough, Jeffrey, Low, Caroline, Reitsma, Andrea, Siu, Stacey, Pine, Polly, Park, Gary, Torneros, Allan, Duan, Matt, Singh, Rajinder, Payan, Donald G., Matsunaga, Takuya, Hitoshi, Yasumichi, and Shimoda, Kazuya

Published
2011
Full Text
View/download PDF

4. Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan

Author

Akizuki, Keiichi, primary, Matsuoka, Hitoshi, additional, Toyama, Takanori, additional, Kamiunten, Ayako, additional, Sekine, Masaaki, additional, Shide, Kotaro, additional, Kameda, Takuro, additional, Kawano, Noriaki, additional, Maeda, Kouichi, additional, Takeuchi, Masanori, additional, Kawano, Hiroshi, additional, Sato, Seiichi, additional, Ishizaki, Junzo, additional, Tahira, Yuki, additional, Shimoda, Haruko, additional, Hidaka, Tomonori, additional, Yamashita, Kiyoshi, additional, Kubuki, Yoko, additional, and Shimoda, Kazuya, additional

Published
2020
Full Text
View/download PDF

6. Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations

Author

Kubuki, Yoko, primary, Shide, Kotaro, additional, Kameda, Takuro, additional, Yamaji, Takumi, additional, Sekine, Masaaki, additional, Kamiunten, Ayako, additional, Akizuki, Keiichi, additional, Shimoda, Haruko, additional, Tahira, Yuki, additional, Nakamura, Kenichi, additional, Abe, Hiroo, additional, Miike, Tadashi, additional, Iwakiri, Hisayoshi, additional, Tahara, Yoshihiro, additional, Sueta, Mitsue, additional, Hashimoto, Kanna, additional, Yamamoto, Shojiro, additional, Hasuike, Satoru, additional, Hidaka, Tomonori, additional, Nagata, Kenji, additional, Kitanaka, Akira, additional, and Shimoda, Kazuya, additional

Published
2017
Full Text
View/download PDF

7. TET2 mutation in diffuse large B-cell lymphoma

Author

Kubuki, Yoko, primary, Yamaji, Takumi, additional, Hidaka, Tomonori, additional, Kameda, Takuro, additional, Shide, Kotaro, additional, Sekine, Masaaki, additional, Kamiunten, Ayako, additional, Akizuki, Keiichi, additional, Shimoda, Haruko, additional, Tahira, Yuuki, additional, Nakamura, Kenichi, additional, Abe, Hiroo, additional, Miike, Tadashi, additional, Iwakiri, Hisayoshi, additional, Tahara, Yoshihiro, additional, Sueta, Mitsue, additional, Yamamoto, Shojiro, additional, Hasuike, Satoru, additional, Nagata, Kenji, additional, Kitanaka, Akira, additional, and Shimoda, Kazuya, additional

Published
2017
Full Text
View/download PDF

8. TET2 Mutation in Adult T-Cell Leukemia/Lymphoma

Author

Shimoda, Kazuya, primary, Shide, Kotaro, additional, Kameda, Takuro, additional, Hidaka, Tomonori, additional, Kubuki, Yoko, additional, Kamiunten, Ayako, additional, Sekine, Masaaki, additional, Akizuki, Keiichi, additional, Shimoda, Haruko, additional, Yamaji, Takumi, additional, Nakamura, Kenichi, additional, Abe, Hiroo, additional, Miike, Tadashi, additional, Iwakiri, Hisayoshi, additional, Tahara, Yoshihiro, additional, Sueta, Mitsue, additional, Yamamoto, Shojiro, additional, Hasuike, Satoru, additional, Nagata, Kenji, additional, and Kitanaka, Akira, additional

Published
2015
Full Text
View/download PDF

11. NS-018, a Potent Novel JAK2 Inhibitor, Effectively Treats Murine MPN Induced by the Janus Kinase 2 (JAK2) V617F Mutant

Author

Shide, Kotaro, primary, Nakaya, Yohei, additional, Kameda, Takuro, additional, Shimoda, Haruko, additional, Hidaka, Tomonori, additional, Kubuki, Yoko, additional, Katayose, Keiko, additional, Matsunaga, Takuya, additional, Homan, Junko, additional, Kotera, Takashi, additional, Shibayama, Hiroshi, additional, Naito, Haruna, additional, and Shimoda, Kazuya, additional

Published
2010
Full Text
View/download PDF

13. JAK2V617F Mutation Selectively Exerts the STAT3 Pathway for Enhancing a Neutrophil Activation Marker.

Author

Oku, Seido, primary, Takenaka, Katsuto, additional, Shide, Kotaro, additional, Kumano, Takashi, additional, Yoshikane, Kikushige, additional, Kuriyama, Takuro, additional, Urata, Shingo, additional, Iwamoto, Chika, additional, Yamauchi, Takuji, additional, Shimoda, Haruko, additional, Miyamoto, Toshihiro, additional, Shimoda, Kazuya, additional, and Akashi, Koichi, additional

Published
2009
Full Text
View/download PDF

15. Efficacy of R723, a Potent and Selective JAK2 Inhibitor, in JAK2V617F-Induced Murine MPD Model.

Author

Shide, Kotaro, primary, Kameda, Takuro, additional, Markovtsov, Vadim, additional, Matsunaga, Takuya, additional, Shimoda, Haruko, additional, Hidaka, Tomonori, additional, Katayose, Keiko, additional, Kubuki, Yoko, additional, Bhamidipati, Somasekhar, additional, Park, Gary, additional, Torneros, Allan, additional, Duan, Matt, additional, Hitoshi, Yasumichi, additional, and Shimoda, Kazuya, additional

Published
2009
Full Text
View/download PDF

16. Elevated Leukocyte Alkaline Phosphatase Scores Induced by Jak2 V617F Mutation

Author

Oku, Seido, primary, Takenaka, Katsuto, primary, Kumano, Takashi, primary, Kuriyama, Takuro, primary, Urata, Shingo, primary, Shide, Kotaro, primary, Shimoda, Haruko, primary, Iwasaki, Hiromi, primary, Miyamoto, Toshihiro, primary, Teshima, Takanori, primary, Nagafuji, Koji, primary, Shimoda, Kazuya, primary, and Akashi, Koichi, primary

Published
2008
Full Text
View/download PDF

18. Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan.

Author

Akizuki, Keiichi, Matsuoka, Hitoshi, Toyama, Takanori, Kamiunten, Ayako, Sekine, Masaaki, Shide, Kotaro, Kameda, Takuro, Kawano, Noriaki, Maeda, Kouichi, Takeuchi, Masanori, Kawano, Hiroshi, Sato, Seiichi, Ishizaki, Junzo, Tahira, Yuki, Shimoda, Haruko, Hidaka, Tomonori, Yamashita, Kiyoshi, Kubuki, Yoko, and Shimoda, Kazuya

Subjects
MULTIPLE myeloma, PROGNOSIS, STEM cell transplantation, DIAGNOSIS, MULTIVARIATE analysis, PLASMACYTOMA
Abstract

The prognosis of multiple myeloma (MM) has improved with the introduction of novel agents. These data are largely derived from clinical trials and might not reflect real-world patient outcomes accurately. We surveyed real-world data from 284 patients newly diagnosed with MM between 2010 and 2018 in Miyazaki Prefecture. The median follow-up period was 32.8 months. The median age at diagnosis was 71 years, with 68% of patients aged >65 years. The International Staging System (ISS) stage at diagnosis was I in 18.4% of patients, II in 34.1%, and III in 47.5%. Bortezomib-containing regimens were preferred as initial treatment; they were used in 147 patients (51.8%). In total, 80% of patients were treated with one or more novel agents (thalidomide, lenalidomide, or bortezomib). Among 228 patients who were treated with novel agents as an initial treatment, the overall response rate (partial response (PR) or better) to initial treatment was 78.4%, and the median time to next treatment (TTNT) was 11.6 months. In the multivariate analysis, PR or better responses to initial treatment were independently favorable prognostic factors for TTNT. The median survival time after initial therapy for patients with novel agents was 56.4 months and 3-year overall survival (OS) was 70.4%. In multivariate analysis, ISS stage I/II disease and PR or better response to initial treatment, and autologous stem cell transplantation (ASCT) were identified as independent prognostic factors for overall survival (OS). [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

20. Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2 V617F-induced Murine Myeloproliferative Neoplasm.

Author

Yamaji T, Shide K, Kameda T, Sekine M, Kamiunten A, Hidaka T, Kubuki Y, Shimoda H, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, and Shimoda K

Subjects
Animals, Janus Kinase 2 antagonists & inhibitors, Janus Kinase 2 metabolism, Liver metabolism, Lung metabolism, Mice, Mice, Transgenic, Myeloproliferative Disorders genetics, Myeloproliferative Disorders metabolism, Myeloproliferative Disorders veterinary, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors pharmacology, Spleen metabolism, Janus Kinase 2 genetics, Mutation, Myeloproliferative Disorders pathology, TYK2 Kinase metabolism
Abstract

Background/aim: In myeloproliferative neoplasms (MPN), Janus kinase 2 (JAK2) is activated by mutations including JAK2V617F (JAK2VF). It is unclear whether JAK kinases [i.e. JAK1, JAK2, JAK3, or tyrosine kinase 2 (TYK2)] other than JAK2 have cooperative actions such as enhancement or suppression of JAK2. If other kinases enhance activation, therapies that co-target them could have a therapeutic efficacy. We examined the role of TYK2 in Jak2VF-induced murine MPN., Materials and Methods: We crossed Jak2VF transgenic mice and Tyk2-knockout (Tyk2KO) mice to generate Jak2VF/Tyk2KO mice. The disease severity and treatment effect with a JAK2 inhibitor was compared between Jak2VF and Jak2VF/Tyk2KO mice., Results: Both types of mice developed MPN, and there were no differences in peripheral blood counts, spleen weight, or survival period. Upon JAK2 inhibitor therapy, both types of mice had equally improved leukocytosis and splenomegaly., Conclusion: TYK2 does not have cooperative effects with JAK2VF upon MPN onset nor in the presence of a JAK2 inhibitor., (Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results